Available Online through   *Research Article*
www.ijptonline.com

PHARMACOKINETIC DRUG INTERACTIONS BETWEEN OMEPRAZOLE WITH CONCOMITANTLY ADMINISTERED CLOPIDOGREL WITH ASPIRIN

Mohammed Salahuddin[1], S Roshan[2*]
[1]Research Scholar, Mewar University, Chittorgarh, Rajasthan, India.
[2]Research Supervisor, Mewar University, Chittorgarh, Rajasthan, India.
Email: Roshansalfi@yahoo.com

Abstract

The present study was aimed to evaluate any possible pharmacokinetic interactions between Omeprazole and clopidogrel. Study was conducted in Male Wistar rats; animals were divided in to three groups, Group I: Omeprazole alone in single dose / day in healthy rats. Group II: clopidogrel alone in single dose / day in healthy rats. Group III: Omeprazole and clopidogrel concomitant administration in healthy rats as a single dose / day. And the treatment was given on day one and day 8 both alone Omeprazole and clopidogrel and concomitantly used both the drugs. The results were showed no significant difference in the t_{max} of Omeprazole alone and combination with clopidogrel on day 1 and day 8 respectively.

These were no significant difference in both c_{max} and t_{max} of clopidogrel alone and combination of Omeprazole on day 1 and day 8 respectively. And there was no significance difference in AUC_{0-t} and AUC_{o-inf} also in alone and combination of both drugs on day 1 and day 8th. Based on the results obtained from kinetic study it is evident that the single dose of Omeprazole with clopidogrel individually and concomitantly treated shows no statistically significant interactions in its pharmacokinetic parameters

Key words: Omeprazole, Clopidogrel, Pharmacokinetic drug interactions, Wistar rats.

Introduction

Drug- Drug Interactions (DDIs) is a phenomenon that occurs when one drug alters the effect of another drug given with it or during its span. Drug interactions may occur when one medicine modifies the pharmacokinetics of another drug or metabolites or may be reflected by the additive pharmacodynamic effects of either drug when taken concomitantly[1,2]. A drug effect may be potentiated, antagonized or otherwise changed by its specific interaction with other drugs, and such interactions can cause potentially harmful and unwanted responses, having severe side effects

may ranging from treatment failure to severe adverse drug events[3]. Literature reveals that approx 10-17% of adverse drug events (ADE) are associated with DDIs in ICU subjects[4]. One of most frequently occurring reasons of Adverse drug reactions (ADRs) is drug interactions and it is more commonly seen in elderly patients due to poly-therapies that affects drug effectiveness[5,6] and it makes therapeutic drug management of patient more complicated[7,8].

The antiplatelet therapy is beneficial in both primary and secondary treatment strategies for cardiovascular disease[9,10]. These antiplatelet agents, however, have recognizable risks in particular, gastrointestinal (GI) complications such as ulceration and related bleeding. These risks may be further compounded by the ancillary use of other adjunctive medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and anticoagulants. Given the high prevalence of antiplatelet therapy in clinical practice, coupled with an increased emphasis on their extended use, especially after implantation of a drug-eluting stent[11,12], it is imperative that physicians know the potential benefits and the associated risks of antiplatelet therapy for primary or secondary prevention of cardiac ischemic events. Clopidogrel, a thienopyridine, is a prodrug that is transformed to an active metabolite, which subsequently blocks platelet activation and aggregation. The active metabolite is formed through the cytochrome P450 (CYP) system after two sequential reactions involving CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4, with CYP2C19 playing a major role[13,14].

Proton pump inhibitor (PPI) medications are often prescribed prophylactically with initiation of clopidogrel, with the goal of reducing the risk of gastrointestinal tract bleeding while taking dual-antiplatelet therapy. Recent studies, however, suggest that PPIs may reduce the inhibitory effect of clopidogrel on platelet aggregation[15,16]. In addition, variations in platelet reactivity have been associated with adverse outcomes following stent implantation[17,18].

Materials and Methods

Materials:

Drugs and chemicals

Omeprazole, clopidogrel, aspirin were procured from aurobindo laboratories as a gift sample. All HPLC grade solvents (methanol and water) were procured from finar chemicals Ltd., Ahmadabad. All chemicals used were analytical grade.

Animal study

Male Wistar rats (weighing 200-220gms) were procured from the animal house CMR College of Pharmacy, Hyderabad. Animals were randomly divided into four groups each group contains six animals. Each rat was

maintained under controlled lab environment atmosphere humidity of 50%, fed with standard pellet diet and water *ad libitum.*

The protocol of animal study was approved by the institutional animal ethical committee with No. IAEC/1657/CMRCP/T2/Ph D-16/77.

Study Design

The rats were grouped as follows:

Group I   : Omeprazole   alone in single dose / day in healthy rats.

Group II   : clopidogrel with aspirin in single dose / day in healthy rats.

Group III   : Omeprazole and clopidogrel with aspirin concomitant administration as a single dose / day in healthy rats.

Collection of Blood Samples

After administration of the drugs, blood samples of 0.5ml were drawn from each anesthetized (isoflurane) rat at pre-determined time intervals was collected from the retro-orbital plexus using a capillary tube into pre-labelled eppendorf tubes containing 10% of K_2EDTA anticoagulant   (20μL). The time intervals for the sample collection were 0 (Pre dose), 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 18 and 24 hrs (post dose), Equal amount of saline was administered to replace blood volume at every blood withdrawal time. Plasma was obtained by centrifuging blood samples by using cooling centrifuge (REMI ULTRA) at 3000 rpm for 5 minutes. The obtained plasma samples were transferred into pre-labelled micro centrifuge tubes and stored at −30°C until bio analysis of pharmacokinetic and pharmacodynamic parameters. As described above, all the procedures were followed on day 8 also. Pharmacokinetic parameters were calculated by non-compartmental analysis by using   Win Nonlin® 5.1 software. Concentrations obtained from the above bio-analytical method were compiled.

Method of Analysis

Preparation of Plasma Samples for HPLC Analysis

Rat plasma (0.5 ml) samples were prepared for chromatography by precipitating proteins with 2.5 ml of ice-cold absolute ethanol for each 0.5 ml of plasma. After centrifugation the ethanol was transferred into a clean tube. The precipitate was re suspended with 1 ml of Acetonitrile by vortexing for 1min. After centrifugation (5000 – 6000 rpm for 10 min), the Acetonitrile was added to the ethanol and the organic mixture was taken to near dryness by a steam of nitrogen at room temperature. Samples were reconstituted in 200μ1 of mobile phase was injected for HPLC

analysis. For HPLC an Inertsil ODS 3V, 250x4.6 mm, C8 column with 5μm particle size and the mobile phase consisting of a mixture of 0.03M potassium dihydrogen ortho phosphate buffer (pH 3), acetonitrile in the ratio of 40:60 (v/v) with a flow rate of 1.2 ml/min. and the eluent was monitored at 240 nm. pantaprazole used as internal standard. The retention times of Omeprazole, clopidogrel, pantaprazole were found to be 8.6, 4.6 and 2.6 min respectively.

Pharmacokinetic Analysis

The pharmacokinetic parameters, peak plasma concentrations (C_{max}) and time to reach peak concentration (t_{max}) were directly obtained from concentration time data. In the present study, AUC_{0-t} refers to the AUC from 0 to 24 hrs, which was determined by linear trapezoidal rule and $AUC_{0-\alpha}$ refers to the AUC from time at zero hours to infinity.

The $AUC_{0-\alpha}$ was calculated using the formula $AUC_{0-t} + [C_{last}/K]$ where C_{last} is the concentration in μg/ml at the last time point and K is the elimination rate constant. Various pharmacokinetic parameters like area under the curve [AUC], elimination half life [t½]. Volume of distribution (V/f) total clearance (Cl/f) and mean residence time for each subject using a non-compartmental analysis by using Win Nonlin® 5.1 software.

Statistical Analysis

Statistical comparisons for the pharmacokinetic – Pharmacodynamic study among, Metformin, Pravastatin alone and in combination groups and plasma concentration – response study among concentrations and time were carried out with student's paired T-Test a value of $P<0.05$ was considered to be statistically significant. Data were reported as mean ± S.E.M linear regressions were used to determine the relationship between total plasma concentrations and pharmacokinetic and pharmacodynamic parameters. The mean concentration versus time profile of Omeprazole, clopidogrel in rat plasma is shown in **Figures 1, 2, 3, and 4.**

Results and Discussion

Mean ± S.E.M, plasma levels (μg/ml) of Omeprazole alone and in Combination with clopidogrel with aspirin on day 1.

Mean ± S.E.M, plasma levels (µg/ml) of Omeprazole alone and in Combination with clopidogrel with aspirin on day 8.

Mean ± S.E.M, plasma levels (µg/ml) of clopidogrel with aspirin alone and in Combination with Omeprazole on day 1.

Mean ± S.E.M, plasma levels (µg/ml) of clopidogrel with aspirin alone and in Combination with Omeprazole on day 8.

Table 1: Mean ± S.E.M, pharmacokinetic parameters of Omeprazole alone and in Combination with clopidogrel with aspirin on day 1.

Parameters	Omeprazole alone	Omeprazole combination with clopidogrel with aspirin
C_{max}	75.74±0.39	76.03±0.12
t_{max}	2±0	2±0
AUC_{0-t} (ng/ml/h)	1072.45±0.74	1056.37±0.52
AUC_{0-inf} (ng/ml/h)	1368.82±2.50	1376.15±1.85
$T_{1/2}$ (h)	6.00±0.28	6.01±0.09

Table 2: Mean ±S.E.M, pharmacokinetic parameters of Omeprazole alone and in Combination with clopidogrel with aspirin on day 8.

Parameters	Omeprazole alone	Omeprazole combination with clopidogrel with aspirin
C_{max}	79.92±2.22	80.41±3.1
t_{max}	2±0	2±0
AUC_{0-t} (ng/ml/h)	1337.36±0.38	1343.38±0.49
AUC_{0-inf} (ng/ml/h)	1596.36±0.63	1613.49±0.74
$T_{1/2}$ (h)	6.04±0.024	6.08±0.018

Table 5: Mean ± S.E.M, pharmacokinetic parameters of clopidogrel with aspirin alone and in Combination with Omeprazole on day 1.

Parameters	clopidogrel alone	clopidogrel with Omeprazole
C_{max}	90.12±3.03	91.83±3.02
t_{max}	2.5±0	2.5±0
AUC_{0-t} (ng/ml/h)	1533.49±0.016	1541.62±0.20
AUC_{0-inf} (ng/ml/h)	1752.33±1.37	1762.16±0.52
$T_{1/2}$ (h)	6.52±0.49	6.57±0.27

Table 6: Mean ±S.E.M, pharmacokinetic parameters of clopidogrel with aspirin alone and in Combination with Omeprazole on day 8.

parameters	clopidogrel alone	clopidogrel with Omeprazole
C_{max}	94.12±3.03	98.83±3.02
t_{max}	2.5±0	2.5±0
AUC_{o-t} (ng/ml/h)	1635.29±2.01	1671.32±3.22
AUC_{o-inf} (ng/ml/h)	1851.32±3.37	1862.13±2.52
$T_{1/2}$ (h)	6.50±0.49	6.50±0.27

Discussion

Clopidogrel is recommended for inhibition of platelet activation and aggregation in patients who are unable to take aspirin or in combination with aspirin in patients with unstable angina or myocardial infarction (MI) or who undergo percutaneous coronary intervention (PCI)[19,20]. Gastrointestinal (GI) bleeding occurs in approximately 2% of patients who are administered dual antiplatelet therapy after PCI[21]; proton pump inhibitors (PPIs) often are prescribed to decrease this risk[20] Addition of a PPI to treatment with aspirin and clopidogrel alone or in combination is recommended for patients with unstable angina or non-ST elevation MI and history of GI bleeding[19]. Of the 4162 patients enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) trial who had been hospitalized for acute coronary syndrome (ACS), 781 (18.8%) received treatment with a PPI[22]. Moreover, PPI use increased with increased number of GI risk factors such as prior GI events and use of anticoagulants[22]. Concomitant treatment with clopidogrel and PPI has been shown to be beneficial for the prevention of GI bleeding.

In the present study, Omeprazole is completely absorbed after oral administration with peak plasma concentration of 75.74±0.39ng/ml after 2hrs of dosing on day 1. In combination with Omeprazole and clopidogrel on day 1, the peak plasma concentration of Omeprazole 76.03±0.12ng/ml occurred 2hr after dosing. There was no significant increase in peak plasma concentration levels. Similarly clopidogrel is completely absorbed after oral administration with peak plasma concentration 90.12±3.03ng/ml occurred 2.5h after dosing on day 1 in combination with Omeprazole and clopidogrel on day 1. The peak plasma concentration of clopidogrel 91.83±3.02ng/ml occurred 2.5h after dosing. There was no significant increase in the peak plasma concentration levels similarly on day 8 of Omeprazole alone and with combination of Omeprazole and clopidogrel on day 8. Peak plasma concentrations are 79.92±2.22ng/ml and

80.41±3.1ng/ml respectively similarly clopidogrel on day 8 and combination with Omeprazole concentrations are 94.12±3.03ng/ml and 98.83±3.02ng/ml respectively. There was no significant difference in peak plasma concentration on day 8 (P>0.05). There is no significant difference in AUC and t_{max} in both alone and combination treatment. The half life was similar with alone and combination treatment on day 1 and day 8. All these changes were not statistically significant (P>0.05). All the results were showed in **Table (1-4).**

Conclusion

In the present study, based on the results obtained from kinetic study it is evident that the single dose of Omeprazole, clopidogrel individually and concomitantly treated diabetic rats did not show any bio statistically significant interactions in its pharmacokinetic parameters.

So, it can be concluded that the concurrent administration of these two drugs have potential benefit in the management of cardiac patients. In addition, due to their insignificant pharmacokinetic interaction the combinational therapy can be safe and highly advantageous in patients with cardiac patients.

References

1. Stockley, I.H.; editor. 2002 Stockley's Drug Interactions, 6 (edn). London: Pharmaceutical Press.

2. Mouly, S.; Meune, C.; Bergmann, JF.; Miniseries: I. Basic science. Uncertainty and inaccuracy of predicting CYPmediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4 Intensive Care Med. 2009, 35,417–29.

3. Krahenbuhl, M.A.; Schlienger, R.; Lampert, M.; Haschke, M.; Drewe, J.; Krahenbuhl, S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf 2007, 30,379–407.

4. Reis, A.M.; De Bortoli, C.H. Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol. 2011,67,625–32.

5. Gallelli,L.; Colosimo, M.; Pirritano, D.; Ferraro, M.; De Fazio, S.; Marigliano, NM. Retrospective evaluation of adverse drug reactions induced by non steroidal anti-inflammatory drugs. Clin Drug Investig.2007, 27,115–22

6. Gallelli, L.; Colosimo M, Tolotta, G.A.; Falcone, D.; Luberto, L.; Curto, LS. Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol. 2010, 66, 137–44.

7. Siniscalchi, A.; Gallelli, L.; Avenoso, T.; Squillace, A.; De Sarro, G. Effects of carbamazepine/oxycodone coadministration in the treatment of trigeminal neuralgia. Ann Pharmacother. 2011, 45, :e33.

8. Canu, B.; Fioravanti, A.; Orlandi, P.; Di Desidero, T.; Alì, G.; Fontanini, G. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia. 2011; 13:217–29.

9. Antman, E.M.; Hand, M.; Armstrong, P.W. Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol, 2008,51, 210-47.

10. Anderson, J.L.; Adams, C.D.; Antman, E.M. ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons, endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007, 50, e1-157.

11. Grines, C.L.; Bonow, R.O.; Casey, D.E Jr. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007, 49,734-9.

12. Bavry, A.A.; Bhatt, D.L.; Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008, 371,2134-43.

13. Juurlink, D.; Gomes, T.; Ko, D. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ, 2009, 180,713-8.

14. Farid, N.A.; Payne, CD.; Small, D.. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther, 2007, 8,735-41.

15. Gilard, M.; Arnaud, B.; Le Gal, G. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006, 4,2508-9.

16. Gilard, M.; Arnaud, B.; Cornily, JC.. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol, 2008, 51,256-60.

17. Barragan, P.; Bouvier, J.L.; Roquebert, P.O et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv. 2003, 59,295-302.

18. Matetzky, S.; Shenkman, B.; Guetta, V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004,109,3171-5

19. Anderson, J.L.; Adams, C.D.; Antman, E.M, et al. ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College Of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation, 2011, 123, e426-e579.

20. Kushner, F.G.; Hand, M.; Smith, S.C. Jr, et al. Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of American College of Cardiology, 2009, 54, 2205-2241.

21. Tanigawa, T.; Watanabe, T.; Nadatani, Y. et al. Gastrointestinal bleeding after percutaneous coronary intervention. Digestion, 2011,83, 153-160.

22. Schreiner, G.C.; Laine, L.; Murphy, S.A.; Cannon, C.P. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed. Critical Pathways in Cardiology, 2007,6, 169-172.

Corresponding Author:

S Roshan[*]

Email: Roshansalfi@yahoo.com